Aytu BioPharma projects $6M-$7M in quarterly sales and marketing spending amid rising EXXUA prescription volumes.
Aytu BioPharma outlined a $6M-$7M quarterly sales and marketing expenditure range for fiscal Q3 2026. The company reported over 920 EXXUA prescriptions in April, signaling early commercial traction for its newly launched product.
The spending guidance aligns with prior quarters but reflects increased investment to support EXXUA’s market penetration. Analysts had anticipated a similar range, though exact consensus estimates were not disclosed. Comparable periods showed steady spending growth as Aytu expanded its commercial footprint.
Management did not provide immediate market reaction details during the earnings call.